Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 85,618	$ 43,584	$ 9,100
General and administrative	61,291	29,159	4,682
Total operating expenses	146,909	72,743	13,782
Loss from operations	(146,909)	(72,743)	(13,782)
Interest income (expense), net	4,746	4	(30)
Other expense, net	(18)	(15)	(31)
Changes in fair value of derivative tranche liability	0	0	(30,000)
Net loss	(142,181)	(72,754)	(43,843)
Net loss attributable to redeemable convertible noncontrolling interests	0	(2,109)	(3,336)
Exchange of redeemable noncontrolling interest shares-deemed dividend	0	(99,994)	0
Net loss attributable to common stockholders/members	$ (142,181)	$ (170,639)	$ (40,507)
Net loss per share, basic	$ (2.17)	$ (4.62)	$ (7.33)
Net loss per share, diluted	$ (2.17)	$ (4.62)	$ (7.33)
Weighted-average number of common shares used in computing net loss per share, basic	65,466,773	36,960,569	5,529,519
Weighted-average number of common shares used in computing net loss per share, diluted	65,466,773	36,960,569	5,529,519